Potentiation of the growth inhibition activity of 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) by herceptin in SKBR-3 human breast cancer cells

Yuan Wan Sun, Ting Kuang Niu, Jin Ming Yang, Chul Hoon Kwon, Kuen Yuan Chen, Kun Ming Chen

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

The 9-aminoacridine derivative, 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) was selected as a potential anticancer agent among a series of sulfur-containing 9-aminoacridine analogues. CK0402 is a topoisomerase II inhibitor and has been shown to exert impressive anticancer activities in both in vitro and in vivo assays. In the present study, we tested the effects of CK0402 in a panel of established human breast cancer cells with varying ER and HER2/neu status. The ER(-) and HER2-overexpressing SKBR-3 cells were the most sensitive cells tested in growth inhibition to CK0402 treatment, and the growth inhibition was in a time- and concentration-dependent manner. In addition, CK0402 also induced stronger G2/M arrest, apoptosis and autophagy in SKBR-3 cells than in ER(+) and HER2(-) MC F-7 cells. To the best of our knowledge, CK0402 is the first 9-aminoacridine analogue to induce autophagy. These findings suggest that CK0402 may be effective against the more aggressive and malignant ER(-) and HER2-overexpressing breast cancer. Towards this end, we further demonstrated that the combination of CK0402 and Herceptin exhibited synergistic/additive cytotoxic effects in SKBR-3 cells using the median-effect/combination-index isobologram methodology (CICI value). Our results indicate that the combination of CK0402 and Herceptin may be a potential therapeutic option against the more aggressive ER(-) and HER2-overexpressing breast cancer.

Original languageEnglish (US)
Pages (from-to)513-518
Number of pages6
JournalExperimental and Therapeutic Medicine
Volume1
Issue number3
DOIs
StatePublished - May 2010

All Science Journal Classification (ASJC) codes

  • Immunology and Microbiology (miscellaneous)
  • Cancer Research

Fingerprint Dive into the research topics of 'Potentiation of the growth inhibition activity of 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) by herceptin in SKBR-3 human breast cancer cells'. Together they form a unique fingerprint.

  • Cite this